Showing results (291-300 of 777) with videos related to
Sort By:
Pageof 78
Blood|October 9, 2004
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implicationsKlaus Podar, Kenneth C AndersonClinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Synopsis of a roundtable on validating novel therapeutics for multiple myelomaWilliam Dalton, Kenneth C AndersonCurrent Opinion in Oncology|November 1, 2002
Thalidomide and immunomodulatory drugs as cancer therapyNoopur Raje, Kenneth C AndersonCell Cycle (Georgetown, Tex.)|April 21, 2010
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathwaysKlaus Podar, Kenneth C AndersonCancer Letters|February 14, 2006
Caveolin-1 as a potential new therapeutic target in multiple myelomaKlaus Podar, Kenneth C AndersonNature Clinical Practice. Oncology|November 3, 2005
Drug insight: thalidomide as a treatment for multiple myelomaShaji Kumar, Kenneth C AndersonExpert Opinion on Drug Metabolism & Toxicology|July 16, 2008
Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicityIris Breitkreutz, Kenneth C AndersonCancer Journal (Sudbury, Mass.)|January 30, 2019
Contribution of Inhibition of Protein Catabolism in MyelomaGiada Bianchi, Kenneth C AndersonCell Cycle (Georgetown, Tex.)|March 14, 2007
Inhibition of VEGF signaling pathways in multiple myeloma and other malignanciesKlaus Podar, Kenneth C AndersonExpert Opinion on Therapeutic Targets|May 26, 2011
CCR1 as a target for multiple myelomaSonia Vallet, Kenneth C AndersonPageof 78